omniture
logo
Search
CLARITY PHARMACEUTICALS
Media Room

Photo News

rss
Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

2026-03-17 21:01 7840
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

2026-01-15 22:02 9019
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

2025-06-13 21:01 4457
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

2025-06-05 21:01 3978
Copper-67 SAR-bisPSMA updates

Copper-67 SAR-bisPSMA updates

2024-10-16 21:03 3913
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

2024-09-12 21:03 3248
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

2024-03-08 22:02 3533
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

2023-11-30 21:59 2848
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

2023-08-25 20:58 3791
Clarity's theranostic prostate cancer trial advances to cohort 2

Clarity's theranostic prostate cancer trial advances to cohort 2

2023-05-24 21:03 3738
Fifty percent recruitment milestone for PROPELLER prostate cancer trial

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

2021-12-01 21:57 2622
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

2021-11-10 22:06 2798